Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 3.96% is 1083% above its 5-year average of -0.40%, near the high end of its 5-year range (-1170.32%–8.87%).
27.13% above its 12-month average of 3.11%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 8.87%.
EBITDA MARGIN
3.96%
EBITDA MARGIN AVG TTM
3.11%
EBITDA MARGIN AVG 3Y
0.62%
EBITDA MARGIN AVG 5Y
-0.40%
EBITDA MARGIN AVG 10Y
-7.52%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+27.13%
CURRENT VS 3Y AVG
+542.94%
CURRENT VS 5Y AVG
+1083.28%
CURRENT VS 10Y AVG
+152.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Teladoc Health, Inc.
Market Cap
$1.14B
EBITDA Margin
3.96%
TTM Avg
3.11%
3Y Avg
0.62%
5Y Avg
-0.40%
Market Cap
$1.89B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$363.33M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$47.08M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.02B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$5.10B
EBITDA Margin
21.06%
TTM Avg
20.50%
3Y Avg
18.63%
5Y Avg
16.67%
Market Cap
$5.77B
EBITDA Margin
-395.82%
TTM Avg
-536.17%
3Y Avg
-471.62%
5Y Avg
-471.62%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Teladoc Health, Inc. (TDOC) | $1.14B | 3.96% | 3.11% | 0.62% | -0.40% |
| NRC Health (NRC)vs › | $479.36M | 21.99% | 25.40% | 28.98% | 31.97% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.89B | 16.41% | 1.22% | -1.65% | 4.31% |
| Shoulder Innovations, Inc. (SI)vs › | $363.33M | -48.80% | -44.09% | -45.35% | -45.35% |
| PDS Biotechnology Corporation (PDSB)vs › | $47.08M | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $3.02B | 22.42% | 17.70% | -0.76% | -37.34% |
| Doximity, Inc. (DOCS)vs › | $5.02B | 35.56% | 38.69% | 36.58% | 34.55% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 21.06% | 20.50% | 18.63% | 16.67% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.77B | -395.82% | -536.17% | -471.62% | -471.62% |
| Chemed Corporation (CHE)vs › | $6.53B | 15.93% | 16.80% | 17.55% | 18.41% |
Gross Margin
73.5%
EBITDA Margin
4.0%
Operating Margin
-7.0%
Net Margin
-7.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 8.87% |
| 2026-03-31 | 7.41% |
| 2025-12-31 | 6.82% |
| 2025-09-30 | -6.62% |
| 2025-06-30 | -0.90% |
| 2025-03-31 | -11.86% |
| 2024-12-31 | 0.89% |
| 2024-09-30 | 1.46% |
| 2024-06-30 | -120.69% |
| 2024-03-31 | -3.11% |
| 2023-12-31 | 5.83% |
| 2023-09-30 | 1.05% |
| 2023-06-30 | -2.44% |
| 2023-03-31 | -3.80% |
| 2022-12-31 | -589.94% |
| 2022-09-30 | -3.03% |
| 2022-06-30 | -513.77% |
| 2022-03-31 | -1170.32% |
| 2021-12-31 | -0.59% |
| 2021-09-30 | -1.50% |
| 2021-06-30 | -5.32% |
| 2021-03-31 | -7.76% |
| 2020-12-31 | -109.75% |
| 2020-09-30 | -2.06% |
| 2020-06-30 | 1.13% |
| 2020-03-31 | -6.25% |
| 2019-12-31 | -6.71% |
| 2019-09-30 | -6.18% |
| 2019-06-30 | -8.55% |
| 2019-03-31 | -8.81% |
| 2018-12-31 | -6.75% |
| 2018-09-30 | -5.44% |
| 2018-06-30 | -10.68% |
| 2018-03-31 | -12.09% |
| 2017-12-31 | -22.24% |
| 2017-09-30 | -22.03% |
| 2017-06-30 | -26.52% |
| 2017-03-31 | -28.43% |
| 2016-12-31 | -28.43% |
| 2016-09-30 | -54.51% |
| 2016-06-30 | -48.72% |
| 2016-03-31 | -49.12% |
| 2015-12-31 | -56.54% |
| 2015-09-30 | -55.60% |
| 2015-06-30 | -83.84% |
| 2015-03-31 | -70.90% |
| 2014-12-31 | -42.89% |
| 2014-09-30 | -29.41% |
| 2014-06-30 | -22.39% |
| 2014-03-31 | -18.86% |
